Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene

Cancer Genet. 2015 Dec;208(12):610-4. doi: 10.1016/j.cancergen.2015.09.004. Epub 2015 Sep 15.

Abstract

We describe a unique case of a woman with acute myeloid leukemia with a new, previously undescribed translocation, t(11;18)(q23;q21.2), affecting the KMT2A (MLL) gene and resulting in an KMT2A(MLL)-ME2 fusion. This disease occurred secondarily following chemotherapy for a different acute myeloid leukemia with the recurrent genetic abnormality inv(16)(p13.1;q22). The secondary leukemia was treated with intensive chemotherapy without allogeneic hematopoietic cell transplantation. Complete remission lasting more than 10 years has been achieved with concurrent and sustained remission of the primary leukemia.

Keywords: KMT2A; MLL gene rearrangement; Therapy-related acute myeloid leukemia; inv(16); long-term remission.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Cytarabine
  • Cytogenetic Analysis
  • Female
  • Granulocyte Colony-Stimulating Factor
  • Histone-Lysine N-Methyltransferase / genetics*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics*
  • Malate Dehydrogenase / genetics*
  • Middle Aged
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Salvage Therapy
  • Translocation, Genetic
  • Vidarabine / analogs & derivatives

Substances

  • KMT2A protein, human
  • Oncogene Proteins, Fusion
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Myeloid-Lymphoid Leukemia Protein
  • Malate Dehydrogenase
  • malic enzyme 2; human
  • Histone-Lysine N-Methyltransferase
  • Vidarabine

Supplementary concepts

  • FLAG protocol